SCHEMBL12492811

SCHEMBL12492811

COc1ccc(CNS(=O)(=O)CCc2ccccc2)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ APLNR P35414 1/20 0.51
▸ TP53 P04637 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ PTK2B Q14289 1/20 0.49
▸ GAA P10253 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ TAS1R3 Q7RTX0 1/20 0.46
▸ TAS1R1 Q7RTX1 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ MMP12 P39900 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12494016 0.88 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KDM4EMAPTAPLNR
SCHEMBL12493456 0.88 MMP8 (0.50) SMN1; SMN2APLNRTP53MEN1KMT2A
SCHEMBL12525710 0.88 APLNR (0.49) ALDH1A1SMN1; SMN2MAPTAPLNRTP53
SCHEMBL12492637 0.87 HTR2A (0.46) ALDH1A1SMN1; SMN2KDM4EMAPTHPGD
SCHEMBL12492849 0.86 APLNR (0.47) ALDH1A1SMN1; SMN2APLNRTP53MEN1
SCHEMBL28970344 0.83 APLNR (0.58) ALDH1A1SMN1; SMN2KDM4EMAPTAPLNR
SCHEMBL12525627 0.82 MTNR1A (0.47) ALDH1A1KDM4EAPLNRTP53MEN1
SCHEMBL12493420 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPTAPLNRTP53
SCHEMBL12492802 0.81 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTAPLNRTP53
SCHEMBL28452492 0.81 APLNR (0.63) ALDH1A1SMN1; SMN2MAPTAPLNRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2683701-B1 OXATHIAZINE DERIVATIVES SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR THEIR PREPARATION, THEIR USAGE AS MEDICAMENT, MEDICAMENT CONTAINING SAME AND ITS USE SANOFI SA (FR) 2014-12-24 — — EP disclosed
EP-2683701-B1 OXATHIAZINE DERIVATIVES SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR THEIR PREPARATION, THEIR USAGE AS MEDICAMENT, MEDICAMENT CONTAINING SAME AND ITS USE SANOFI SA (FR) 2014-12-24 — — EP disclosed
US-8846666-B2 Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof SANOFI (FR) 2014-09-30 — — US disclosed
US-8846666-B2 Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof SANOFI (FR) 2014-09-30 — — US disclosed
US-20140066437-A1 OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF SANOFI (FR) 2014-03-06 — — US disclosed
US-20140066437-A1 OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF SANOFI (FR) 2014-03-06 — — US disclosed
EP-2683703-A1 NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF SANOFI (FR) 2014-01-15 — — EP disclosed
WO-2012120058-A1 OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF SANOFI (FR) 2012-09-13 — — WO disclosed
WO-2012120057-A1 NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF SANOFI (FR) 2012-09-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066437-A1 OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF SLC5A2, SLC5A1, CYP11B2 ALDH1A1 693/4885SMN1; SMN2 3344/4885KDM4E 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback